Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment—Analyses from the German clinical RCC-Registry-Reference-Cited by-同舟云学术

Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment—Analyses from the German clinical RCC-Registry

Published:2018-10 Issue:10 Volume:36 Page:470.e1-470.e9
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Goebell Peter J.^ORCID,Müller Lothar,Hübner Andreas,Harich Hanns-Detlev,Boller Emil,Koska Michaela,Jänicke Martina,Marschner Norbert^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference35 articles.

1. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet];Ferlay,2013

2. Gesellschaft der epidemiologischen Krebsregister,2017

3. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review;Gupta;Cancer Treat Rev,2008

4. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

5. Treatment options for metastatic renal cell carcinoma: a review;Athar;Can J Urol,2008

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients;JU Open Plus;2024-04

2. Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review;Urologia Internationalis;2024

3. Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma;Urologic Oncology: Seminars and Original Investigations;2023-09

4. Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective study;Współczesna Onkologia;2023

5. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme;Future Oncology;2021-11